Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07309432 · ClinicalTrials.gov registry record · Phase 3
Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy
A Phase 3 study of Allergic Conjunctivitis, sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 350
- Enrollment target
- 1
- Study location
NCT07309432 is a Phase 3 study of Allergic Conjunctivitis that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 350 participants, above the 117-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (199% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07309432, a Phase 3 study of Allergic Conjunctivitis, is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 350 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is researching 2 experimental drugs, REGN5713 and REGN5715. The study drugs will be either of these drugs given alone (either REGN5713 or REGN5715) or given together (REGN5713 and REGN5715) to reduce eye allergy signs and symptoms due to birch tree pollen allergy. The aim of the study is to see how safe and effective the study drugs are at lowering eye allergy signs and symptoms compared with placebo. The study will also evaluate whether the combination (REGN5713-5715) has different effectiveness than REGN5713 or REGN5715 alone. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much of the study drugs is in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the drug less effective or could lead to side effects)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG REGN5713
- DRUG REGN5715
Study Locations (1)
Massachusetts
- Andover Eye Associates - Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2026-01-10 |
| Est. Completion | 2027-06-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07309432
The ClinicalTrials.gov registry entry for NCT07309432 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 117-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (199% higher). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Conjunctivitis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07309432 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07309432 about?
NCT07309432 is a clinical study titled "Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy". This study is researching 2 experimental drugs, REGN5713 and REGN5715. The study drugs will be either of these drugs given alone (either REGN5713 or REGN5715) or given together (REGN5713 and REGN5715) to reduce eye allergy signs and symptoms due to birch tree pollen allergy. The aim of the study is...
What is the current status of trial NCT07309432?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 350 participants. The study started on 2026-01-10. Estimated completion is 2027-06-15.
What conditions does trial NCT07309432 study?
This clinical trial studies the following conditions: Allergic Conjunctivitis.
What interventions are being tested in trial NCT07309432?
The interventions under investigation include: Placebo (DRUG), REGN5713 (DRUG), REGN5715 (DRUG).
Who is sponsoring clinical trial NCT07309432?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07309432 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis
COMPLETED · Phase 3
-
ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
COMPLETED · Phase 3
-
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
COMPLETED · Phase 3
-
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
COMPLETED · Phase 3
-
An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis
COMPLETED · Phase 3
-
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.